Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment

Journal of Neuroscience

Volumn 23, Issue 15, 2003, Pages 6264-6271

  Deplanque, Dominique ^a,d   Gelé, Patrick ^a   Pétrault, Olivier ^a   Six, Isabelle ^a   Furman, Christophe ^b   Bouly, Muriel ^b   Nion, Stéphane ^c   Dupuis, Bernard ^a   Leys, Didier ^d   Fruchart, Jean Charles ^b   Cecchelli, Roméo ^c   Staels, Bart ^b   Duriez, Patrick ^b   Bordet, Régis ^a  

^a UNIV LILLE   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIVERSITÉ D'ARTOIS   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Adhesion proteins; Inflammation; Mouse; Neuroprotection; Oxidative stress; PPAR ; Prevention; Stroke

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN E; BRAIN ENZYME; CELL ADHESION MOLECULE; FENOFIBRATE; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LIPID; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA ACTIVATOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN PROTECTION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; MIDDLE CEREBRAL ARTERY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; RECEPTOR DEFICIENCY; STROKE; VASODILATATION;

EID: 0038720453     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-15-06264.2003     Document Type: Article

References (45)

1. Amarenco P (2001) Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology 57[Suppl 2]:S35-44.
2. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA (2001) Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32:980-986.
3. Aspey BS, Ehteshami S, Hurst CM, Pereira S, Harrison MJ (1989) Effect of bezafibrate on the sequelae of acute experimental focal cerebral ischaemia. J Neurol Neurosurg Psychiatry 52:1432-1434.
4. Bastide M, Bordet R, Pu Q, Robin E, Puisieux F, Dupuis B (1999) Relationship between inward rectifier potassium current impairment and brain injury after cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 19:1309-1315.
5. Bastide M, Gelé P, Pétrault O, Pu Q, Caliez A, Robin E, Deplanque D, Duriez P, Bordet R. (2003) Delayed cerebrovascular protective effect of lipopolysaccharide in parallel to brain ischemic tolerance. J Cereb Blood Flow Metab 23:399-405.
6. Bishop-Bailey D (2000) Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129:823-834.
7. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ (2001) Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial. VA-HIT Study Group. Circulation 103:2828-2833.
8. Bordet R, Deplanque D, Maboudou P, Puisieux F, Pu Q, Robin E, Martin A, Bastide M, Leys D, Lhermitte M, Dupuis B (2000) Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide-induced brain ischemic tolerance. J Cereb Blood Flow Metab 20:1190-1196.
9. Chan PH (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21:2-14.
10. Chen J, Simon R (1997) Ischemic tolerance in the rat brain. Neurology 48:306-311.
11. Connolly ES, Winfree CJ, Stern DM, Solomon RA, Pinsky DJ (1996) Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. Neurosurgery 38:523-532.
12. Cullingford TE, Bhakoo K, Peuchen S, Dolphin CT, Patel R, Clark JB (1998) Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem 70:1366-1375.
13. Dehouck MP, Meresse S, Delorme P, Fruchart JC, Cecchelli R (1990) An easier, reproducible and mass-production method to study the blood-brain barrier in vitro. J Neurochem 54:1798-1801.
14. Delerive P, De Bosscher K, Besnard S, Berghe WV, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B (1999) PPARalpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274:32048-32054.
15. Deplanque D, Bastide M, Bordet R (2000) Ischaemic preconditioning of the endothelium and smooth muscle of cerebral arteries. Trends Pharmacol Sci 21:332-333.
16. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fievet C, Wright SD, Staels B (2002) Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277:48051-48057.
17. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95:8880-8885.
18. Fisher M, Jones S, Sacco RL (1994) Prophylactic neuroprotection for cerebral ischemia. Stroke 25:1075-1080.
19. Fruchart JC, Duriez P, Staels B (1999) Peroxisome proliferator-activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10:245-257.
20. Goldberg DM, Spooner RJ (1983) Glutathione reductase in methods in enzymatic analysis (Bermeyer HU, ed) pp 258-265. New York: Academic.
21. Habig WH, Pabst MJ, Jakoby WB (1974) Glutathione S-transferase, the first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130-7139.
22. Hankey GJ, Warlow CP (1999) Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 354:1457-1463.
23. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50:3-11.
24. Jander S, Pohl J, Gillen C, Schroeter M, Stoll G (1996) Vascular cell adhesion molecule-1 mRNA is expressed in immune-mediated and ischemic injury of the rat nervous system. J Neuroimmunol 70:75-80.
25. Jonas S (1995) Prophylactic pharmacologic neuroprotection against focal cerebral ischemia. Ann NY Acad Sci 765:21-25.
26. Kainu T, Wikström AC, Gustafsson JA, Pelto-Huikko M (1994) Localization of the peroxisome proliferator-activated receptor in the brain. NeuroReport 5:2481-2485.
27. Kawai N, Keep RF, Betz AL (1997) Hyperglycemia and the vascular effects of cerebral ischemia. Stroke 28:149-154.
28. Laskowitz DT, Sheng H, Bart RD, Joyner KA, Roses AD, Warner DS (1997) Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab 17:753-758.
29. Lee JM, Grabb MC, Zipfel GJ, Choi DW (2000) Brain tissue responses to ischemia. J Clin Invest 106:723-731.
30. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FZ (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012-3022.
31. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J (2001) Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial-FAT). Cardiovasc Res 52:290-298.
32. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J (1999) PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125-3131.
33. Paglia DE, Valentine WN (1967) Studies on the quantitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158-169.
34. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FZ, Auwerx J (1997) Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 272:27307-27312.
35. Poynter ME, Daynes RA (1998) Peroxisome proliferator-activated receptor a activation modulates cellular redox status, represses nuclear factor-κB signaling and reduces inflammatory cytokine production in aging. J Biol Chem 273:32833-32841.
36. Puisieux F, Deplanque D, Pu Q, Souil E, Bastide M, Bordet R (2000) Differential role of nitric oxide pathway and heat shock protein in preconditioning and lipopolysaccharide-induced brain ischemic tolerance. Eur J Pharmacol 389:71-78.
37. Ramassamy C, Krzywkowski P, Averill D, Lussier-Cacan S, Theroux L, Christen Y, Davignon J, Poirier J (2001) Impact of Apo E deficiency on oxidative insults and antioxidant levels in the brain. Mol Brain Res 86:76-83.
38. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393:790-793.
39. Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R (2002) Activation of the peroxisome proliferator-activated receptor a protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol 2:1-10.
40. Uryu S, Harada J, Hisamoto M, Oda T (2002) Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res 924:229-236.
41. Vaughan CJ, Delanty N (1999) Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30:1969-1973.
42. Wang X, Siren AL, Liu Y, Yue TL, Barone FC, Feueurstein GZ (1994) Upregulation of intercellular adhesion molecule-1 (ICAM-1) on brain microvascular endothelial cells in rat ischemic cortex. Mol Brain Res 26:61-68.
43. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16:1027-1040.
44. Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550.
45. Yoo HY, Chang MS, Rho HM (1999) Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid. Gene 234:87-91.